The analysts added that 2026 iPhone estimates are “softer (down ~7% y/y), after a better 2025E,” and warned that a “new foldable iPhone with 2-3x ASP could delay upgrades,” hurting demand for Skyworks ...

Investing.com -- Mizuho has cut its ratings on Rivian and Texas Instruments, citing weakening electric vehicle (EV) demand ...

Investing.com -- Iranian Supreme Leader Ayatollah Ali Khamenei rejected claims made by U.S. President Donald Trump regarding the destruction of Iran’s nuclear capabilities. "The U.S. president proudly ...

Investing.com -- Cooper Cos. shares rose over 4% in premarket trading Monday after the Wall Street Journal reported that activist investor Jana Partners built a stake in the company and plans to push ...

Investing.com -- Beyond Meat (NASDAQ:BYND) stock soared 70% in pre-market trading Monday, rising from $0.64 to $1.08, continuing momentum after Friday’s 24% gain.

Investing.com - JPMorgan downgraded Oracle’s credit rating to Neutral from Overweight on Monday, citing substantial capital needs and limited visibility into the company’s financing strategy for its ...

Investing.com -- Boeing stock gained 1.7% in premarket Monday trade after the Federal Aviation Administration (FAA) approved an increase in production rates for the company’s 737 MAX aircraft.

“AI does not look like a bubble yet based on our valuation monitor,” analysts at Citi wrote, though they added that “there ...

Morgan Stanley said ADP’s Paris Airports business trades on the “least demanding valuation” among peers, with shares ...

Investing.com -- Olema Pharmaceuticals shares fell 28% in premarket trading Monday after the drug developer released data from an early-mid stage breast cancer trial that was overshadowed by ...

Investing.com -- Sable Offshore Corp. shares climbed 15% in premarket trading Monday after U.S. Energy Secretary Chris Wright voiced support for the company’s stalled California oil project.

The BLA seeks approval for RP1 in combination with nivolumab to treat advanced melanoma patients who progress on anti-PD-1 containing regimens. The FDA has set a Prescription Drug User Fee Act (PDUFA) ...